Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$6.89 -2.1%	$9.54	$2.09 ▼ $14.84	$488.43M	0.05	5.53 million shs	3.21 million shs
AMT American Tower	$171.00 -0.6%	$192.83	$154.58 ▼ $219.10	$79.75B	0.67	2.42 million shs	2.27 million shs
CHEOY Cochlear	$101.96 -0.6%	$108.76	$73.73 ▼ $114.50	$13.36B	0.91	3,291 shs	4,716 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-6.38%	-12.11%	-22.47%	-34.75%	+23.51%
AMT American Tower	-0.10%	-5.46%	-12.19%	-15.64%	-17.37%
CHEOY Cochlear	+1.70%	-0.22%	-5.98%	+7.21%	+22.97%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	1.1526 of 5 stars	3.3	2.0	0.0	0.0	1.9	1.7	0.0
AMT American Tower	4.9197 of 5 stars	4.4	3.0	2.5	3.1	2.8	2.5	1.9
CHEOY Cochlear	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$15.00	117.71% Upside
AMT American Tower	2.82	Moderate Buy	$217.36	27.11% Upside
CHEOY Cochlear	1.50	Reduce	N/A	N/A

Current Analyst Ratings

Latest CHEOY, ADR, AMT, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	AMT American Tower	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$183.00 ➝ $196.00
4/8/2024	AMT American Tower	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$205.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/5/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$224.00 ➝ $234.00
2/28/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$235.00 ➝ $228.00
2/28/2024	AMT American Tower	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$236.00 ➝ $230.00
2/13/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
1/24/2024	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$13.00
1/24/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$229.00 ➝ $224.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$430K	1,135.89	N/A	N/A	$2.75 per share	2.51
AMT American Tower	$11.14B	7.16	$9.84 per share	17.38	$23.30 per share	7.34
CHEOY Cochlear	$1.32B	10.14	N/A	N/A	N/A	∞

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Estimated)
AMT American Tower	$1.48B	$3.18	53.77	16.19	1.42	13.31%	12.80%	2.24%	4/30/2024 (Confirmed)
CHEOY Cochlear	N/A	N/A	0.00	44.52	N/A	N/A	N/A	N/A	N/A

Latest CHEOY, ADR, AMT, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/30/2024	N/A	AMT American Tower	$2.45	N/A	-$2.45	N/A	N/A	N/A
2/27/2024	12/31/2023	AMT American Tower	$2.10	$0.94	-$1.16	$0.18	$2.74 billion	$2.79 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMT American Tower	$6.48	3.79%	+21.62%	203.77%	N/A
CHEOY Cochlear	$1.16	1.14%	N/A	N/A	N/A

Latest CHEOY, ADR, AMT, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/16/2024	CHEOY Cochlear		$0.0336	1%	3/21/2024	3/22/2024	4/30/2024
3/14/2024	AMT American Tower	quarterly	$1.62	3.3%	4/11/2024	4/12/2024	4/26/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
AMT American Tower	3.29	0.69	0.69
CHEOY Cochlear	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMT American Tower	92.69%
CHEOY Cochlear	N/A

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
AMT American Tower	0.24%
CHEOY Cochlear	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.89 million	67.99 million	Optionable
AMT American Tower	5,643	466.35 million	465.23 million	Optionable
CHEOY Cochlear	4,800	130.99 million	N/A	Not Optionable

CHEOY, ADR, AMT, and ALT Headlines

Source	Headline
	ACCC waives through Cochlear’s revised rival buy innovationaus.com - April 4 at 1:33 AM
	Cochlear's Oticon Implants Acquisition Approved by Australian Regulator marketwatch.com - April 3 at 8:32 PM
	ACCC will not oppose revised Cochlear, Oticon Medical transaction accc.gov.au - April 3 at 8:32 PM
	Can a vaccine slow down the Cochlear train? afr.com - March 27 at 9:19 PM
	Cochlear Ltd's Dividend Analysis finance.yahoo.com - March 20 at 7:06 PM
	Cochlear Limited (ASX: COH) - Share Price and Research intelligentinvestor.com.au - March 16 at 10:23 AM
	Cochlear Implant Scheme now renamed ‘Shravana Sanjeevini’ starofmysore.com - March 12 at 12:04 PM
	Cochlear calls for action in Washington D.C. ahead of World Hearing Day prnewswire.com - February 28 at 4:48 PM
	New Tarabichi Mondy Cochlear Implant Center pledges major contributions towards addressing hearing loss and deafness in the UAE zawya.com - February 28 at 9:10 AM
	Cochlear Limited - Depositary Receipt () (CHEOY) Price Target Increased by 11.05% to 94.91 msn.com - February 25 at 12:53 AM
	Cochlear announces 2024 winners of annual scholarships prnewswire.com - February 22 at 10:15 AM
	Cochlear price target raised by A$20 at UBS, here's why realmoney.thestreet.com - February 19 at 9:07 PM
	Cochlear price target raised by A$18 at Morgan Stanley, here's why realmoney.thestreet.com - February 19 at 9:07 PM
	What we learnt from Cochlear, Wesptac, Ampol and Bendigo’s results afr.com - February 19 at 9:47 AM
	Cochlear lifts dividend thanks to strong first-half results thewest.com.au - February 18 at 11:42 PM
	Citi Reaffirms Their Sell Rating on Cochlear Limited (CHEOF) markets.businessinsider.com - February 18 at 11:42 PM
	Cochlear's first-half profit up 35pct to $191 million msn.com - February 18 at 11:42 PM
	Cochlear’s profit is booming, but says plenty of room to grow theaustralian.com.au - February 18 at 11:42 PM
	Cochlear share price falls despite 29% dividend boost fool.com.au - February 18 at 11:42 PM
	Cochlear surpasses expectations sharecafe.com.au - February 18 at 6:41 PM
	Cochlear Hoists Dividend on 35% Jump in 1H Profit -- Update marketwatch.com - February 18 at 6:41 PM
	Cochlear’s big first half delivers best dividend in a decade afr.com - February 18 at 6:41 PM
	Cochlear Implant Market to Accumulate a Valuation of USD 4.0 Billion by 2030, Advancing at a 10.36% CAGR \| MarketDigits finance.yahoo.com - February 16 at 2:30 PM
	Morgans downgrades Cochlear Limited (CHEOF) to a Hold markets.businessinsider.com - February 12 at 8:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

American Tower

NYSE:AMT

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

Cochlear

OTCMKTS:CHEOY

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial